Inhibiting growth of Clostridioides difficile by restoring valerate, produced by the intestinal microbiota

McDonald, Julie A.K., Mullish, Benjamin H., Pechlivanis, Alexandros, Liu, Zhigang, Brignardello, Jerusa, Kao, Dina, Holmes, Elaine, Li, Jia V., Clarke, Thomas B., Thursz, Mark R. and Marchesi, Julian R. ORCID: https://orcid.org/0000-0002-7994-5239 2018. Inhibiting growth of Clostridioides difficile by restoring valerate, produced by the intestinal microbiota. Gastroenterology 155 (5) , pp. 1495-1507. 10.1053/j.gastro.2018.07.014

Preview

PDF - Accepted Post-Print Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (8MB) | Preview

Abstract

Background & Aims Fecal microbiota transplantation (FMT) is effective for treating recurrent Clostridioides difficile infection (CDI), but there are concerns about its long-term safety. Understanding the mechanisms of the effects of FMT could help us design safer, targeted therapies. We aimed to identify microbial metabolites that are important for C difficile growth. Methods We used a CDI chemostat model as a tool to study the effects of FMT in vitro. The following analyses were performed: C difficile plate counts, 16S rRNA gene sequencing, proton nuclear magnetic resonance spectroscopy, and ultra-performance liquid chromatography and mass spectrometry bile acid profiling. FMT mixtures were prepared using fresh fecal samples provided by donors enrolled in an FMT program in the United Kingdom. Results from chemostat experiments were validated using human stool samples, C difficile batch cultures, and C57BL/6 mice with CDI. Human stool samples were collected from 16 patients with recurrent CDI and healthy donors (n = 5) participating in an FMT trial in Canada. Results In the CDI chemostat model, clindamycin decreased valerate and deoxycholic acid concentrations and increased C difficile total viable counts and valerate precursors, taurocholic acid, and succinate concentrations. After we stopped adding clindamycin, levels of bile acids and succinate recovered, whereas levels of valerate and valerate precursors did not. In the CDI chemostat model, FMT increased valerate concentrations and decreased C difficile total viable counts (94% decrease), spore counts (86% decrease), and valerate precursor concentrations; concentrations of bile acids were unchanged. In stool samples from patients with CDI, valerate was depleted before FMT but restored after FMT. Clostridioides difficile batch cultures confirmed that valerate decreased vegetative growth, and that taurocholic acid was required for germination but had no effect on vegetative growth. Clostridioides difficile total viable counts were decreased by 95% in mice with CDI given glycerol trivalerate compared with phosphate buffered saline. Conclusions We identified valerate as a metabolite that is depleted with clindamycin and only recovered with FMT. Valerate is a target for a rationally designed recurrent CDI therapy.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	WB Saunders
ISSN:	0016-5085
Date of First Compliant Deposit:	9 August 2018
Date of Acceptance:	9 July 2018
Last Modified:	09 Nov 2023 16:51
URI:	https://orca.cardiff.ac.uk/id/eprint/114080

Citation Data

Cited 106 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item